# Explainable AI for Breast Density & Breast Cancer: Review (2015â€“2025)

This repository accompanies our systematic review on explainable AI (XAI) for **breast density assessment** and **breast cancer (BC) diagnosis** across imaging modalities (mammography, DBT, MRI, ultrasound, histopathology, clinical reports). We synthesize **47 studies**, methods, datasets, and outcomes with a special focus on BI-RADSâ€“aligned density assessment and model explainability.

> **Why it matters:** In 2022 there were **~2.3M new BC cases** and **~670k deaths** worldwide; incidence and mortality continue risingâ€”particularly in Asia and Africaâ€”underscoring the need for accurate, explainable, and deployable AI tools.

---

## Contents

- [Key Stats](#key-stats)
- [Imaging Modalities & Whatâ€™s Different](#imaging-modalities--whats-different)
- [Public Datasets (with Links)](#public-datasets-with-links)
- [Benchmarked Tasks & Representative Results](#benchmarked-tasks--representative-results)
  - [Binary Tasks](#binary-tasks)
  - [Multi-class Tasks](#multi-class-tasks)
- [How to Cite](#how-to-cite)

---

## Key Stats

- **47** peerâ€‘reviewed studies synthesized (2020â€“2025).
- **Publication peaks:** 2022 (**6** studies) and 2025 (**5** in-press/online first) per our PRISMA-tracked corpus.
- **Modalities covered:** mammography, DBT, MRI, ultrasound, PET/CT, histopathology, clinical reports.
- **Focus:** performance **and** explainability (saliency/attribution), dataset mapping, and clinical alignment.


## ğŸŒ Global Impact

Breast cancer remains a critical global health issue with rising incidence worldwide.

<div align="center">

### Projected Growth by Region (2022 â†’ 2050)

| Region | 2022 Cases | 2050 Projection | Growth Rate |
|--------|------------|-----------------|-------------|
| ğŸŒ **Asia** | ~1,000,000 | ~1,400,000 | â¬†ï¸ **+40%** |
| ğŸŒ **Africa** | ~200,000 | ~450,000 | â¬†ï¸ **+125%** |
| ğŸŒ **Latin America** | ~230,000 | ~350,000 | â¬†ï¸ **+52%** |
| ğŸŒ **Europe** | ~550,000 | ~600,000 | â¬†ï¸ **+9%** |
| ğŸŒ **North America** | ~300,000 | ~400,000 | â¬†ï¸ **+33%** |

</div>

> ğŸ’¡ **2022 Statistics**: 2.3 million new cases and ~670,000 deaths globally, accounting for nearly 7% of all cancer-related fatalities.

---
---


## Imaging Modalities & Whatâ€™s Different

| Modality | What it is (1â€“2 words) | Strengths | Limitations / Considerations | Typical Use |
|---|---|---|---|---|
| **Mammography (FFDM)** | X-ray | Screening workhorse; detects microcalcifications; wide availability; low cost | Lower sensitivity in dense breasts; ionizing radiation; compression discomfort | Population screening; baseline assessment |
| **Digital Breast Tomosynthesis (DBT)** | 3D X-ray | Reduces tissue overlap; improves lesion conspicuity; better recall rates vs 2D | Higher dose than 2D; larger data volume; specialized reading | Screening/diagnostic follow-up in dense breasts |
| **Contrast-Enhanced Mammography (CEM)** | X-ray + contrast | Highlights tumor vascularity; often higher specificity vs mammo/US; faster than MRI | Contrast risks; slightly higher dose; availability varies | Problem solving; extent of disease |
| **Ultrasound (B-mode)** | Sound waves | No radiation; good for cysts/solid masses; adjunct in dense breasts; accessible | Operator-dependent; limited for microcalcifications; variable specificity | Supplemental screening/diagnostic work-up |
| **Contrast-Enhanced Ultrasound (CEUS)** | US + microbubbles | Assesses perfusion/microvasculature; can improve lesion characterization | Protocols not standardized; contrast safety/availability | Characterization and therapy monitoring |
| **Breast MRI (DCE-MRI)** | Magnetic resonance | Very high sensitivity; whole-breast coverage; useful for occult/extent | Costly; variable specificity; contrast required (gadolinium) | High-risk screening; pre-op staging; problem solving |
| **BSGI / MBI** | Nuclear imaging | Functional uptake; helpful in dense tissue | Higher radiation; limited availability; cost | Problem solving when MRI/CEM unavailable |
| **PET/CT** | Metabolic + anatomic | Staging; metastasis detection; treatment response | Higher dose; lower spatial resolution for small lesions; cost | Systemic staging and response assessment |
| **Thermography** | Infrared heat map | Non-contact; low cost | Low specificity; not recommended as standalone | Research/adjunct only |
| **Photoacoustic Imaging (PAI)** | Opticalâ€“US hybrid | Non-ionizing; vascular/oxygenation contrast | Early-stage/limited availability; standardization needed | Research; lesion characterization pilots |


## Public Datasets (with Links)

> **Note:** Many datasets require data use agreements or registration; ensure proper approvals before downloading.

| Dataset | Modality | Size (approx.) | Link |
|---|---|---:|---|
| **MIAS** | Mammography | 322 images | https://www.kaggle.com/datasets/kmader/mias-mammography |
| **DDSM** | Mammography | ~10,000 images (film scans) | http://www.eng.usf.edu/cvprg/mammography/database.html |
| **CBIS-DDSM** | Mammography (curated for ML) | ~2,500 cases | https://www.cancerimagingarchive.net/collection/cbis-ddsm/ |
| **INbreast** | Mammography (FFDM) | 410 images | https://paperswithcode.com/dataset/inbreast |
| **BUSI** | Ultrasound | 780 images | https://www.kaggle.com/datasets/aryashah2k/breast-ultrasound-images-dataset |
| **BreakHis** | Histopathology | 7,909 images | https://www.kaggle.com/datasets/kmader/breast-cancer-histology-images |
| **BACH** | Histopathology | 400 images | https://paperswithcode.com/dataset/bach |
| **TCGA-BRCA** | WSIs + clinical | >1,000 cases | https://portal.gdc.cancer.gov/projects/TCGA-BRCA |
| **TCIA Breast MRI** | MRI | varies | https://www.cancerimagingarchive.net/collections/ (search â€œBreast MRIâ€) |

---

## Benchmarked Tasks & Representative Results

### Binary Tasks

- **Breast density: dense vs. nonâ€‘dense (A/B vs. C/D).** Mohamed et al. (2018) â€” CNN from scratch and pretrained; **AUC 0.988/0.986** on 22k mammograms. [Ref. 51]

- **Breast density (clinical deployment).** Lehman et al. (2019) â€” ResNetâ€‘18; **94.0%** of binary assessments endorsed by radiologists (95% CI 94.0â€“95.0). [Ref. 41]

- **Breast density (dense vs. fatty).** Ciritsis et al. (2019) â€” 11â€‘layer CNN; **99%/96%** agreement (MLO/CC) with radiologists on external 200â€‘image test set. [Ref. 13]

- **Breast density via MRI.** Jing et al. (2024) â€” transfer learning on 514 MRIs; **Acc 76.3%**, **Îº=0.71**. [Ref. 31]

- **INbreast texture radiomics (C/D vs. A/B).** Xu et al. (2024) â€” residual learning; **Acc 96.8%** on 410 images from 115 patients. [Ref. 83]

- **Multiâ€‘site robustness.** Gandomkar et al. (2020) â€” Inceptionâ€‘V3 fineâ€‘tuning across 9 units/3 vendors; **Acc 92.0%** on 3,813 mammos (test: 150 images from 14 units). [Ref. 22]

> See **Table 7â€“9** in the manuscript for a complete binaryâ€‘task matrix (goals, datasets, methods, metrics).


### Multi-class Tasks

- **4â€‘class BIâ€‘RADS density (Aâ€“D).** Lehman et al. (2019) â€” ResNetâ€‘18; **Acc 77%**; main confusion between B and C. [Ref. 41]

- **4â€‘class BIâ€‘RADS density (Aâ€“D) with external agreement.** Ciritsis et al. (2019) â€” 11â€‘layer dCNN; **Acc 90.9% (MLO), 90.1% (CC)**; **agreement 92.2%/87.4%**. [Ref. 13]

- **4â€‘class BIâ€‘RADS density at scale.** Chen et al. (2025) â€” InceptionV3; **Acc 94.6%** (Cat A), **AP 0.895â€“0.953**, **~0.027 s/image** on 57,282 mammograms. [Ref. 11]

- **Imbalanceâ€‘aware ensembles.** Lopez et al. (2022) â€” RegL ensemble (VGGâ€‘19, ResNeXt4D, DenseNet121); **Acc 84.6%** on 1,081 mammograms. [Ref. 45]

- **Dualâ€‘view fusion.** Busaleh et al. (2022) â€” TwoViewDensityNet; **Acc 95.83% (DDSM), 96% (INbreast)**; **AUC 0.9951**. [Ref. 9]

- **Preprocessing + attention.** Kate et al. (2022) â€” InceptionV3 + GSA + Kapur entropy; **Acc 97.98%** on DDSM. [Ref. 35]

- **Clinical multiâ€‘site BIâ€‘RADS.** Lewin et al. (2023) â€” CNN; **Acc 84.6â€“89.7%**, â‰¤1â€‘category deviation from radiologists. [Ref. 42]

- **GANâ€‘augmented density.** Saffari et al. (2020) â€” cGAN+CNN; **Precision/Sensitivity 97.85%**, **Specificity 99.28%**. [Ref. 68]

- **5â€‘class molecular subtype (CMMD).** Ben et al. (2025) â€” multimodal CNN+metadata; **AUC 88.87%**, outperformed imagingâ€‘only (**61.3%**). [Ref. 6]

- **Microcalcification triage (BIâ€‘RADS 1/2â€“3/4â€“5).** Schonenberger et al. (2021) â€” three CNNs; **Validation 99.5â€“99.6%**; clinical accuracy 39% (BIâ€‘RADS 4), 80.9% (BIâ€‘RADS 5). [Ref. 70]

> See **Table 10** in the manuscript for a complete multiâ€‘class matrix.

### ğŸ“ˆ Binary Classification Performance

#### Breast Density Assessment (Dense vs. Non-Dense)

| Model | Accuracy | AUC | Sensitivity | Specificity | Year | Reference |
|-------|----------|-----|-------------|-------------|------|-----------|
| **Mohamed et al. CNN** | - | **0.9882** | - | - | 2018 | [[1]](#ref1) |
| **Kate et al. InceptionV3** | **97.98%** | - | - | - | 2022 | [[2]](#ref2) |
| **Lewin et al. CNN** | 97.4% | - | - | - | 2023 | [[3]](#ref3) |
| **Xu et al. Residual** | 96.8% | - | - | - | 2018 | [[4]](#ref4) |
| **Kriti et al. SVM** | 94.4% | - | - | - | 2015 | [[5]](#ref5) |
| **Ciritsis et al. dCNN** | 99% MLO<br>96% CC | - | - | - | 2019 | [[6]](#ref6) |

#### Cancer Detection (Benign vs. Malignant)

| Model | Accuracy | AUC | Sensitivity | Specificity | Year | Reference |
|-------|----------|-----|-------------|-------------|------|-----------|
| **Mahmood et al. CNN+LSTM** | - | **0.99** | **99%** | - | 2024 | [[7]](#ref7) |
| **Abdel et al. DBN+BPNN** | **99.68%** | - | - | - | 2016 | [[8]](#ref8) |
| **Puttegowda et al. YOLOv3** | 98.8% | 0.99 | 97.2% | - | 2025 | [[9]](#ref9) |
| **Suh et al. DenseNet-169** | - | 0.952 | 87% | 88% | 2020 | [[10]](#ref10) |
| **Shimokawa et al. BilAD** | 84% | 0.90 | 73% | 93% | 2023 | [[11]](#ref11) |

### ğŸ“Š Multi-Class BI-RADS Classification (A-D)

| Model | Accuracy | AUC | Classes | Year | Reference |
|-------|----------|-----|---------|------|-----------|
| **Kate et al. InceptionV3+GSA** | **97.98%** | - | 4-class | 2022 | [[2]](#ref2) |
| **Busaleh et al. TwoViewDensityNet** | 95.83% | **0.9951** | 4-class | 2022 | [[12]](#ref12) |
| **Chen et al. InceptionV3** | 94.6% | 0.895-0.953 | 4-class | 2025 | [[13]](#ref13) |
| **Deng et al. SE-Attention CNN** | 92.17% | - | 4-class | 2020 | [[14]](#ref14) |
| **Xu et al. Residual Learning** | 92.6% | - | 4-class | 2018 | [[4]](#ref4) |
| **Ciritsis et al. dCNN** | 90.9% MLO<br>90.1% CC | - | 4-class | 2019 | [[6]](#ref6) |
| **Pawar et al. DenseNet** | 90.06% | 0.9625 | 4-class | 2022 | [[15]](#ref15) |

### ğŸ¯ Segmentation Performance

| Model | Accuracy | Dice | Jaccard | Pearson's r | Year | Reference |
|-------|----------|------|---------|-------------|------|-----------|
| **Saffari et al. cGAN-UNet** | **98%** | **0.88** | 0.78 | - | 2020 | [[16]](#ref16) |
| **Ahn et al. CNN** | - | - | - | **0.96** | 2017 | [[17]](#ref17) |
| **Li et al. DCNN** | - | 0.79Â±0.13 | - | 0.97 (CV) | 2018 | [[18]](#ref18) |
| **Lee et al. FCN** | - | - | - | 0.85 | 2018 | [[19]](#ref19) |

---

## ğŸ¤– AI Framework

Our review analyzes a comprehensive AI and XAI workflow for breast cancer analysis:

### ğŸ”„ Complete Pipeline
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚         INPUT LAYER                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â€¢ Medical Imaging (Mammography, MRI)   â”‚
â”‚ â€¢ Clinical Data (History, Demographics)â”‚
â”‚ â€¢ Histopathology (Tissue samples)      â”‚
â”‚ â€¢ Genomic Data (Gene expression)       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                 â”‚
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      PREPROCESSING LAYER                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â€¢ Image: Normalization, Augmentation    â”‚
â”‚ â€¢ Data: Missing value imputation        â”‚
â”‚ â€¢ Feature: Texture analysis, Radiomics  â”‚
â”‚ â€¢ Genomic: Quality control, filtering   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                 â”‚
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚   MULTIMODAL FEATURE INTEGRATION        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â€¢ Correlation Analysis                  â”‚
â”‚ â€¢ Feature Selection                     â”‚
â”‚ â€¢ Dimensionality Reduction (PCA, t-SNE) â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                 â”‚
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚         AI MODELS LAYER                 â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ CNN:                                    â”‚
â”‚  â€¢ ResNet, DenseNet, EfficientNet       â”‚
â”‚ Ensemble:                               â”‚
â”‚  â€¢ Random Forest, XGBoost               â”‚
â”‚ Transformer:                            â”‚
â”‚  â€¢ Vision Transformers, BERT            â”‚
â”‚ Hybrid:                                 â”‚
â”‚  â€¢ CNN-RNN, CNN-LSTM, Multimodal Fusion â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                 â”‚
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚        XAI METHODS LAYER                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â€¢ LIME (Local explanations)             â”‚
â”‚ â€¢ SHAP (Shapley values)                 â”‚
â”‚ â€¢ Grad-CAM (Visual heatmaps)            â”‚
â”‚ â€¢ Attention Mechanisms                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                 â”‚
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚         OUTPUT LAYER                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Predictions:                            â”‚
â”‚  â€¢ Malignant/Benign classification      â”‚
â”‚  â€¢ BI-RADS density categories           â”‚
â”‚  â€¢ Risk scores, Survival estimates      â”‚
â”‚ Explanations:                           â”‚
â”‚  â€¢ Feature importance rankings          â”‚
â”‚  â€¢ Visual heatmaps                      â”‚
â”‚  â€¢ Decision rules                       â”‚
â”‚ Clinical Support:                       â”‚
â”‚  â€¢ Treatment recommendations            â”‚
â”‚  â€¢ Prognostic assessments               â”‚
â”‚  â€¢ Risk stratification                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                 â”‚
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚   CLINICAL DECISION SUPPORT SYSTEM      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â€¢ Interactive Dashboard                 â”‚
â”‚ â€¢ Physician Interface                   â”‚
â”‚ â€¢ Treatment Planning                    â”‚
â”‚ â€¢ Patient Communication                 â”‚
â”‚ â€¢ EHR Integration                       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### ğŸ§  Popular Architectures Analyzed

**Convolutional Neural Networks (CNNs):**
- ResNet (18, 50, 152)
- DenseNet (121, 169)
- VGG (16, 19)
- InceptionV3
- EfficientNet (B0-B7)

**Transformer-Based Models:**
- Vision Transformers (ViT)
- BERT-based architectures
- MobileNet-v2 with ViT

**Hybrid Approaches:**
- CNN-LSTM combinations
- CNN-SVM integration
- Multi-stream networks
- cGAN-UNet

**Ensemble Methods:**
- Random Forest
- XGBoost
- Voting classifiers
- Multi-model ensembles

---

## ğŸ“ˆ Results

### ğŸ“Š Publication Trends

Our PRISMA-guided systematic review identified:

<div align="center">

| Metric | Count |
|--------|-------|
| **Initial Records** | 502 |
| **Records Screened** | 480 |
| **Full-Text Assessed** | 100 |
| **Studies Included** | **47** |
| **Time Period** | 2020-2025 |

</div>

### ğŸ“š Top Publishers

| Publisher | Studies | Percentage |
|-----------|---------|------------|
| **Elsevier** | 9 | 19.1% |
| **MDPI** | 5 | 10.6% |
| **Springer** | 4 | 8.5% |
| **RSNA** | 3 | 6.4% |
| **SPIE** | 3 | 6.4% |
| **IEEE** | 3 | 6.4% |
| **Others** | 20 | 42.6% |

### ğŸ“… Publication Year Distribution

| Year | Studies | Key Highlights |
|------|---------|----------------|
| **2015** | 5 | Early ML approaches (SVM, PCA) |
| **2016** | 3 | Deep Belief Networks emerge |
| **2017** | 4 | Transfer learning adoption |
| **2018** | 5 | CNN dominance begins |
| **2019** | 4 | XAI methods integration |
| **2020** | 2 | COVID-19 impact on publications |
| **2021** | 1 | Virtual conferences era |
| **2022** | 6 | **Peak year** - Multi-modal fusion |
| **2023** | 4 | Transformer models |
| **2024** | 5 | LLMs for radiology reports |
| **2025** | 5 | Multimodal learning, Clinical validation |

---

## Links to Papers (selection)

> Full bibliographic details and DOIs are provided in our manuscript reference list (see Tables 7â€“10). Examples from our corpus:
- DOI: [10.1002/jmri.29058](https://doi.org/10.1002/jmri.29058)
- DOI: [10.1002/mp.12683](https://doi.org/10.1002/mp.12683)
- DOI: [10.1002/mp.12763](https://doi.org/10.1002/mp.12763)
- DOI: [10.1002/mp.14573](https://doi.org/10.1002/mp.14573)
- DOI: [10.1007/978-3-319-21212-8_7](https://doi.org/10.1007/978-3-319-21212-8_7)
- DOI: [10.1007/978-3-319-52277-7_13](https://doi.org/10.1007/978-3-319-52277-7_13)
- DOI: [10.1007/s00330-017-5143-2](https://doi.org/10.1007/s00330-017-5143-2)
- DOI: [10.1007/s00330-019-06357-1](https://doi.org/10.1007/s00330-019-06357-1)
- DOI: [10.1007/s00330-020-06564-2](https://doi.org/10.1007/s00330-020-06564-2)
- DOI: [10.1007/s00330-023-09474-7](https://doi.org/10.1007/s00330-023-09474-7)
- DOI: [10.1007/s11548-018-1794-0](https://doi.org/10.1007/s11548-018-1794-0)
- DOI: [10.1007/s12194-022-00686-y](https://doi.org/10.1007/s12194-022-00686-y)
- DOI: [10.1007/s41870-022-00930-z](https://doi.org/10.1007/s41870-022-00930-z)
- DOI: [10.1016/B978-0-323-95462-4](https://doi.org/10.1016/B978-0-323-95462-4)
- DOI: [10.1016/j.bspc.2025.107607](https://doi.org/10.1016/j.bspc.2025.107607)
- DOI: [10.1016/j.clinimag.2023.06.023](https://doi.org/10.1016/j.clinimag.2023.06.023)
- DOI: [10.1016/j.cmpb.2020.105489](https://doi.org/10.1016/j.cmpb.2020.105489)
- DOI: [10.1016/j.cmpb.2022.106885](https://doi.org/10.1016/j.cmpb.2022.106885)
- DOI: [10.1016/j.compbiomed.2014.10.006](https://doi.org/10.1016/j.compbiomed.2014.10.006)
- DOI: [10.1016/j.compmedimag.2016.07](https://doi.org/10.1016/j.compmedimag.2016.07)
- DOI: [10.1016/j.eswa.2015.10.015](https://doi.org/10.1016/j.eswa.2015.10.015)
- DOI: [10.1016/j.eswa.2024.123747](https://doi.org/10.1016/j.eswa.2024.123747)
- DOI: [10.1016/j.glt.2025.04.007](https://doi.org/10.1016/j.glt.2025.04.007)
- DOI: [10.1016/j.jmir.2021.10.004](https://doi.org/10.1016/j.jmir.2021.10.004)
- DOI: [10.1016/j.lana.2025.101096](https://doi.org/10.1016/j.lana.2025.101096)
- DOI: [10.1038/s41467-020-17410-5](https://doi.org/10.1038/s41467-020-17410-5)
- DOI: [10.1038/s41598-018-19369-6](https://doi.org/10.1038/s41598-018-19369-6)
- DOI: [10.1038/s41598-025-95275-5](https://doi.org/10.1038/s41598-025-95275-5)
- DOI: [10.1038/s41746-019-0214-6](https://doi.org/10.1038/s41746-019-0214-6)
- DOI: [10.1088/1361-6560/aa9f87](https://doi.org/10.1088/1361-6560/aa9f87)

## Research Gaps Identified

- **External validity & domain shift:** Many studies report singleâ€‘site performance; few include multiâ€‘vendor, multiâ€‘site **external validation** or headâ€‘toâ€‘head clinical reader studies (density and diagnosis).  
- **Patientâ€‘level splits & leakage controls:** Several reports lack strict **patientâ€‘level** partitioning across views/time, risking optimistic estimatesâ€”especially in small datasets.  
- **Imbalance handling & calibration:** Class imbalance (e.g., BIâ€‘RADS A/B vs. C/D; benign vs. malignant) is often mitigated with reâ€‘sampling, but **probability calibration** and **decisionâ€‘threshold protocols** are underâ€‘reported.  
- **Explainability verification:** Saliency/prototype maps are shown qualitatively; **prospective humanâ€‘factors or counterfactual tests** validating that explanations improve safety/utility are rare.  
- **Fairness & subgroup performance:** Limited analyses across **age, breast density, scanner/vendor, and ethnicity**; few report **subgroup CIs** or fairness metrics.  
- **Ordinal structure underused:** For BIâ€‘RADS density (A<B<C<D), many models ignore **ordinal constraints**, which can waste supervision and harm clinical consistency.  
- **Multimodal fusion and reports:** Sparse integration of **mammography/DBT + US/MRI + clinical notes**; limited use of reportâ€‘mined labels and weak supervision.  
- **Robustness & security:** Few stress tests for **adversarial noise**, compression, view mismatches, or **outâ€‘ofâ€‘distribution** detection in screening workflows.  
- **Benchmarking standards:** Heterogeneous **metrics, splits, and preprocessing** prevent applesâ€‘toâ€‘apples comparisons; public leaderboards for density are lacking.  
- **Regulatory & deployment evidence:** Minimal **prospective trials**, workflow impact assessments, or postâ€‘deployment monitoring (drift, alert fatigue, equity).  


## Future Work & Recommendations

- **Strong external validation:** Preâ€‘register **multiâ€‘site** (â‰¥3 vendors) studies with patientâ€‘level splits and **external test sets**; report **CIs** via bootstrap and **calibration** (ECE, reliability curves).  
- **Ordinalâ€‘aware objectives:** For density, prefer **ordinal regression/losses** (e.g., CORAL/CMOL, isotonic calibration) or **hierarchical heads** that respect A<B<C<D.  
- **Uncertainty & thresholding:** Report **wellâ€‘calibrated probabilities**, operating points tied to clinical **PPV/NPV** targets, and **abstention** (deferâ€‘toâ€‘human) policies.  
- **Explainability that works:** Pair saliency/prototype methods with **sanity checks**, **region perturbation**, and **readerâ€‘inâ€‘theâ€‘loop** studies measuring trust, time, and error reduction.  
- **Fairness audits:** Stratify performance by **density, age, race/ethnicity, site/vendor**; publish subgroup CIs and mitigation plans when gaps appear.  
- **Multimodal fusion:** Explore **DBT+US/MRI**, **imaging+EHR** fusion, and **reportâ€‘supervision**; evaluate crossâ€‘modal consistency and failure modes.  
- **Foundation & selfâ€‘supervised models:** Leverage large **SSL/foundation** encoders adapted to breast imaging; study **fewâ€‘shot** transfer and labelâ€‘efficient fineâ€‘tuning.  
- **Federated & privacyâ€‘preserving learning:** Use **federated**, DPâ€‘aware methods to unlock diverse sites while protecting PHI; benchmark against pooledâ€‘data baselines.  
- **Robustness testing:** Stress test against **compression, resolution, view order**, and synthetic artifacts; add **OOD detectors** in screening triage.  
- **Open benchmarks:** Release **patientâ€‘level** splits, preprocessing scripts, and **evaluation toolkits**; pursue public challenges for **binary** (dense vs nonâ€‘dense; cancer vs nonâ€‘cancer) and **multiâ€‘class** (BIâ€‘RADS Aâ€“D; lesion types).  
- **Prospective trials & workflow impact:** Design **prospective** reader studies measuring sensitivity at matched specificity, timeâ€‘toâ€‘decision, recall/biopsy rates, and downstream outcomes.  

## Repo Structure (suggested)

```
.
â”œâ”€â”€ README.md
â”œâ”€â”€ data/                 # (optional) metadata, NOT raw PHI
â”œâ”€â”€ figures/              # schematic diagrams and saliency examples
â”œâ”€â”€ notebooks/            # exploratory notebooks
â””â”€â”€ src/                  # helper scripts for metrics and visualization
```

---

## Disclaimer

This repository is for research and educational purposes. Clinical deployment requires regulatory clearance, clinical trials, and appropriate QA processes.
